CN101821621A - 筛选、治疗和诊断 - Google Patents

筛选、治疗和诊断 Download PDF

Info

Publication number
CN101821621A
CN101821621A CN200880106081A CN200880106081A CN101821621A CN 101821621 A CN101821621 A CN 101821621A CN 200880106081 A CN200880106081 A CN 200880106081A CN 200880106081 A CN200880106081 A CN 200880106081A CN 101821621 A CN101821621 A CN 101821621A
Authority
CN
China
Prior art keywords
trem
ligand
cell
receptor
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN200880106081A
Other languages
English (en)
Chinese (zh)
Inventor
M·科隆纳
J·科勒斯耐-泰特
P·帕尼纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Bioxell SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioxell SpA filed Critical Bioxell SpA
Publication of CN101821621A publication Critical patent/CN101821621A/zh
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN200880106081A 2007-07-23 2008-07-23 筛选、治疗和诊断 Withdrawn CN101821621A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96161507P 2007-07-23 2007-07-23
US60/961,615 2007-07-23
PCT/EP2008/059668 WO2009013319A1 (en) 2007-07-23 2008-07-23 Screening, therapy and diagnosis

Publications (1)

Publication Number Publication Date
CN101821621A true CN101821621A (zh) 2010-09-01

Family

ID=39816994

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880106081A Withdrawn CN101821621A (zh) 2007-07-23 2008-07-23 筛选、治疗和诊断

Country Status (5)

Country Link
US (1) US20100306863A1 (enExample)
EP (1) EP2174131A1 (enExample)
JP (1) JP2010534828A (enExample)
CN (1) CN101821621A (enExample)
WO (1) WO2009013319A1 (enExample)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102517287A (zh) * 2012-01-10 2012-06-27 广西大学 抑制水牛TREM1基因表达的shRNA、慢病毒表达载体及其构建方法和应用
CN105765382A (zh) * 2013-08-09 2016-07-13 伊诺特伦公司 用于预测具有心血管疾病或心血管事件的风险的方法和试剂盒
CN111157741A (zh) * 2019-12-30 2020-05-15 广州市妇女儿童医疗中心 髓系细胞触发受体1在制备胃炎诊断或治疗试剂中的应用及试剂盒
CN112526143A (zh) * 2020-12-03 2021-03-19 中山大学附属第五医院 髓系细胞触发受体2作为新型冠状病毒肺炎诊断或治疗靶点的应用
CN113424798A (zh) * 2015-04-13 2021-09-24 再生元制药公司 人源化SIRPα-IL15敲入小鼠及其使用方法
CN113687081A (zh) * 2021-05-19 2021-11-23 大汉生物科技(广东)有限公司 髓系细胞触发受体2在制备脓毒症相关功能产品中的应用
CN114174536A (zh) * 2019-07-15 2022-03-11 百时美施贵宝公司 抗trem-1抗体及其用途
CN114736957A (zh) * 2022-04-15 2022-07-12 中国人民解放军空军军医大学 外泌体介导rna casc15干预阿尔茨海默症突触损失的应用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8393201B2 (en) 2010-09-21 2013-03-12 Webtech Wireless Inc. Sensing ignition by voltage monitoring
RU2463606C1 (ru) * 2011-08-17 2012-10-10 Учреждение Российской академии медицинских наук Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний Сибирского отделения Российской академии медицинских наук (УРАМН НИИ КПССЗ СО РАМН) Способ ранней диагностики осложненного системного воспалительного ответа у пациентов, оперированных в условиях искусственного кровообращения
EP2814842B1 (en) 2012-02-15 2018-08-22 Novo Nordisk A/S Antibodies that bind peptidoglycan recognition protein 1
HRP20200875T8 (hr) 2012-09-07 2021-04-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Inhibitorni peptidi porijeklom od aktivirajućeg receptora eksprimiranog na mijeloidnim stanicama-1 (trem-1)-sličnog transkripta 1 (tlt-1) i nihove upotrebe
WO2019161080A1 (en) * 2018-02-14 2019-08-22 Yale University Compositions for modulation of a trem or treml protein and methods of use
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
EP3932421A4 (en) * 2019-03-01 2023-03-22 University of Tsukuba Composition for use in treatment of allergic diseases
EP4388136A4 (en) * 2021-08-17 2025-07-23 Biomeme Inc METHODS FOR CHARACTERIZING INFECTIONS AND METHODS FOR DEVELOPING CORRESPONDING TESTS
CN116908446B (zh) * 2023-06-27 2024-05-07 广州市妇女儿童医疗中心 用于诊断川崎病冠状动脉瘤的生物标志物及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) * 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4716111A (en) * 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
IT1164225B (it) * 1983-05-13 1987-04-08 Anic Spa Analoghi retro-invertiti del pentapeptide potenziante la bradichina bpp5a e metodi per la loro preparazione
US5413923A (en) * 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
EP1690935A3 (en) * 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5814318A (en) * 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
JP2938569B2 (ja) * 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993011236A1 (en) * 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5916771A (en) * 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
CA2342376C (en) * 2001-03-20 2013-11-12 Marco Colonna A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US20090081199A1 (en) * 2001-03-20 2009-03-26 Bioxell S.P.A. Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
GB0305478D0 (en) * 2003-03-10 2003-04-16 Bioxell Spa Diagnostic and prognostic compounds and method

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102517287A (zh) * 2012-01-10 2012-06-27 广西大学 抑制水牛TREM1基因表达的shRNA、慢病毒表达载体及其构建方法和应用
CN102517287B (zh) * 2012-01-10 2013-09-11 广西大学 抑制水牛TREM1基因表达的shRNA、慢病毒表达载体及其构建方法和应用
CN105765382A (zh) * 2013-08-09 2016-07-13 伊诺特伦公司 用于预测具有心血管疾病或心血管事件的风险的方法和试剂盒
CN113424798A (zh) * 2015-04-13 2021-09-24 再生元制药公司 人源化SIRPα-IL15敲入小鼠及其使用方法
CN114174536A (zh) * 2019-07-15 2022-03-11 百时美施贵宝公司 抗trem-1抗体及其用途
CN111157741A (zh) * 2019-12-30 2020-05-15 广州市妇女儿童医疗中心 髓系细胞触发受体1在制备胃炎诊断或治疗试剂中的应用及试剂盒
CN112526143A (zh) * 2020-12-03 2021-03-19 中山大学附属第五医院 髓系细胞触发受体2作为新型冠状病毒肺炎诊断或治疗靶点的应用
CN113687081A (zh) * 2021-05-19 2021-11-23 大汉生物科技(广东)有限公司 髓系细胞触发受体2在制备脓毒症相关功能产品中的应用
CN114736957A (zh) * 2022-04-15 2022-07-12 中国人民解放军空军军医大学 外泌体介导rna casc15干预阿尔茨海默症突触损失的应用
CN114736957B (zh) * 2022-04-15 2024-03-12 中国人民解放军空军军医大学 外泌体介导rna casc15干预阿尔茨海默症突触损失的应用

Also Published As

Publication number Publication date
EP2174131A1 (en) 2010-04-14
US20100306863A1 (en) 2010-12-02
WO2009013319A1 (en) 2009-01-29
JP2010534828A (ja) 2010-11-11

Similar Documents

Publication Publication Date Title
CN101821621A (zh) 筛选、治疗和诊断
Hofbauer et al. β2-microglobulin triggers NLRP3 inflammasome activation in tumor-associated macrophages to promote multiple myeloma progression
Rizzo et al. Cryptococcus extracellular vesicles properties and their use as vaccine platforms
Chen et al. Broad and direct interaction between TLR and Siglec families of pattern recognition receptors and its regulation by Neu1
Seider et al. Immune evasion, stress resistance, and efficient nutrient acquisition are crucial for intracellular survival of Candida glabrata within macrophages
Chen et al. Increased gene copy number of DEFA1/DEFA3 worsens sepsis by inducing endothelial pyroptosis
Sidiq et al. Nod2: a critical regulator of ileal microbiota and Crohn’s disease
Rogers et al. Syk-dependent cytokine induction by Dectin-1 reveals a novel pattern recognition pathway for C type lectins
Hamerman et al. The expanding roles of ITAM adapters FcRγ and DAP12 in myeloid cells
Risitano et al. Paroxysmal nocturnal hemoglobinuria: pathophysiology, natural history and treatment options in the era of biological agents
US8013116B2 (en) Therapeutic peptides and method
Chiang et al. Differences in granule morphology yet equally impaired exocytosis among cytotoxic T cells and NK cells from Chediak–Higashi syndrome patients
Das et al. Membrane-bound complement regulatory proteins as biomarkers and potential therapeutic targets for SLE
Gander-Bui et al. Targeted removal of macrophage-secreted interleukin-1 receptor antagonist protects against lethal Candida albicans sepsis
UA130114C2 (uk) Антитіло до альфа-синуклеїну
Metzemaekers et al. Fast and furious: the neutrophil and its armamentarium in health and disease
Kurz et al. Noncanonical Hippo signalling in the regulation of leukocyte function
Wagner et al. Cek1 regulates ß (1, 3)-glucan exposure through calcineurin effectors in Candida albicans
Launder et al. Immunity to pathogenic mucosal C. albicans infections mediated by oral megakaryocytes activated by IL-17 and candidalysin
US20190262425A1 (en) Uses of il-41
Rizzo et al. New insights into Cryptococcus extracellular vesicles suggest a new structural model and an antifungal vaccine strategy
Zhang et al. Inefficient antimicrobial functions of innate phagocytes render infant mice more susceptible to bacterial infection
Boursalian et al. Stability of naive and memory phenotypes on resting CD4 T cells in vivo
Stappers et al. Recognition of DHN-melanin by MelLec, is required for protective immunity to Aspergillus
Bian et al. S100A4 deficiency is associated with efficient bacterial clearance and protects against joint destruction during Staphylococcal infection

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: NOVO NORDISK CO., LTD.

Free format text: FORMER OWNER: BIOXELL S. P. A.

Effective date: 20110131

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: MILAN, ITALY TO: BAGSVARD, DENMARK

TA01 Transfer of patent application right

Effective date of registration: 20110131

Address after: Denmark bagsvaerd

Applicant after: NOVO Nordisk A/S

Address before: Milan Italy

Applicant before: Bioxell SPA

C04 Withdrawal of patent application after publication (patent law 2001)
WW01 Invention patent application withdrawn after publication

Open date: 20100901